KIF20A and head and neck cancer: The work by Yusuke Tomita et al. brought to light the capacity of KIF20A-derived long peptides to invoke both CD4+ T-cell and CD8+ T-cell responses, showcasing the versatility of KIF20A-LPs in immunotherapy, especially for head-and-neck malignant tumors (HNMT), offering a glimmer of hope for patients with these challenging conditions [91].